These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 9604228

  • 1. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T, Holle LH, Schroth HJ, Garth H.
    Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
    [Abstract] [Full Text] [Related]

  • 2. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
    Bojarska-Szmygin A, Ciechanek R.
    Wiad Lek; 2003 May; 56(7-8):303-7. PubMed ID: 14969154
    [Abstract] [Full Text] [Related]

  • 3. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE.
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [Abstract] [Full Text] [Related]

  • 4. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
    Bojarska-Szmygin A, Janicki K, Pietura R, Janicka L.
    Ann Univ Mariae Curie Sklodowska Med; 2003 Dec; 58(1):248-53. PubMed ID: 15314994
    [Abstract] [Full Text] [Related]

  • 5. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
    Massart C, Gibassier J, d'Herbomez M.
    Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
    [Abstract] [Full Text] [Related]

  • 6. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, Seissler J.
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [Abstract] [Full Text] [Related]

  • 7. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE, Basedow Study Group.
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [Abstract] [Full Text] [Related]

  • 8. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H, Miehle K, Mayer A, Tuschy U, Hentschel B, Paschke R.
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [Abstract] [Full Text] [Related]

  • 9. [Thyrotropin receptor antibodies (TRAb) as a test of surgical treatment effectiveness in Graves-Basedow's diseases].
    Bojarska-Szmygin A, Ciechanek R, Jezierska B, Zaorska-Rajca J.
    Pol Merkur Lekarski; 2002 Sep; 13(75):196-9. PubMed ID: 12474569
    [Abstract] [Full Text] [Related]

  • 10. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
    Gauna AT, Guillén CE, Sartorio GC, Soto RJ.
    Medicina (B Aires); 1992 Sep; 52(3):207-12. PubMed ID: 1364158
    [Abstract] [Full Text] [Related]

  • 11. Are porcine and human TSH receptor antibody measurements comparable?
    Zöphel K, von Landenberg P, Roggenbuck D, Wunderlich G, Kotzerke J, Lackner KJ.
    Clin Lab; 2008 Sep; 54(1-2):1-8. PubMed ID: 18510037
    [Abstract] [Full Text] [Related]

  • 12. TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves' disease patients.
    Aleksić A, Aleksić Z, Stojanović M.
    Hell J Nucl Med; 2009 Sep; 12(2):146-50. PubMed ID: 19675869
    [Abstract] [Full Text] [Related]

  • 13. [Antithyrotropin receptor antibodies in a series of Basedow's disease].
    Vidal E, Antoine E, Nadalon S, Cevallos R, Bournaud E, Vandroux JC, Bordessoule D, Loustaud V, Weinbreck P, Liozon F.
    Ann Med Interne (Paris); 1988 Sep; 139(5):331-5. PubMed ID: 2462393
    [Abstract] [Full Text] [Related]

  • 14. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, Lian WC, Huang WS, Kuo SW.
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [Abstract] [Full Text] [Related]

  • 15. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M, Minich WB, Willenberg HS, Papewalis C, Seissler J, Feldkamp J, Bergmann A, Scherbaum WA, Morgenthaler NG.
    Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
    [Abstract] [Full Text] [Related]

  • 16. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O.
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [Abstract] [Full Text] [Related]

  • 17. [TSH anti-receptor antibodies in Graves' disease].
    Sérgio MR, Godinho C, Guerra L, Agapito A, Fonseca F, Costa C.
    Acta Med Port; 1996 Jan; 9(7-9):229-31. PubMed ID: 9005701
    [Abstract] [Full Text] [Related]

  • 18. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
    Takasu N, Kamijo K, Sato Y, Yoshimura H, Nagata A, Ochi Y.
    Clin Exp Pharmacol Physiol; 2004 Jan; 31(5-6):314-9. PubMed ID: 15191404
    [Abstract] [Full Text] [Related]

  • 19. Lymphocytes resided in the thyroid are the main source of TSH-receptor antibodies in Basedow's-Graves' disease?
    Leövey A, Nagy E, Balazs G, Bako G.
    Exp Clin Endocrinol; 1992 Jan; 99(3):147-50. PubMed ID: 1526264
    [Abstract] [Full Text] [Related]

  • 20. Analysis of ¹³¹I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study.
    Zheng W, Jian T, Guizhi Z, Zhaowei M, Renfei W.
    Nucl Med Commun; 2012 Jan; 33(1):97-101. PubMed ID: 22008631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.